Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 79
Selected: 0
NCT IDTitle
NCT03976856Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
NCT02314819A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
NCT02601248Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT05511051A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
NCT03873532A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT03160833A Study of HMPL-453 in Patients With Advanced Solid Malignancies
NCT02897479A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
NCT03951623The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT00655733Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT02017236A Food Effect Phase I Study of the Volitinib in Healthy Subjects
NCT02601274Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT02590952A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
NCT05842525Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT03251378A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT02589821Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT03627520A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT03778229Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT04755075Surufatinib Hepatic Impairment Study
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT02133157Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT01985555Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT01773018Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT04272957A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT02966171A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT04923945Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT06437353Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT03977090Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
NCT03860948A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
NCT05173142A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
NCT04755088Surufatinib Renal Impairment Study